Literature DB >> 11901859

Molecular diagnostic testing for infectious diseases using TMA technology.

C S Hill1.   

Abstract

Molecular diagnostic tests based on nucleic acid amplification technologies (NAATs) have become widely established in clinical microbiology laboratories in recent years. The acceptance of these tests has been driven by the development of more accurate and less labor-intensive commercial assay kits by diagnostic manufacturers. Infectious disease diagnostic assays using transcription-mediated amplification (TMA) NAAT have become increasingly popular in many clinical microbiology laboratories. Recent technology developments have improved the performance and simplified the use of the TMA assays. These new technologies have been applied to the development of multiplex TMA tests to improve the testing accuracy for organisms, such as Chlamydia trachomatis and Neisseria gonorrhoeae in clinical microbiology laboratories. TMA tests for HIV-1 and HCV have also led to improvements in blood bank testing which can improve the safety of the public blood supply.

Entities:  

Mesh:

Year:  2001        PMID: 11901859     DOI: 10.1586/14737159.1.4.445

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  10 in total

1.  Comparison of three nucleic acid amplification tests for detection of Chlamydia trachomatis in urine specimens.

Authors:  Charlotte A Gaydos; Mellisa Theodore; Nicholas Dalesio; Billie Jo Wood; Thomas C Quinn
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Comparison of the APTIMA CT and GC assays with the APTIMA combo 2 assay, the Abbott LCx assay, and direct fluorescent-antibody and culture assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

Authors:  B Boyadzhyan; T Yashina; J H Yatabe; M Patnaik; C S Hill
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

3.  Specific versus nonspecific isothermal DNA amplification through thermophilic polymerase and nicking enzyme activities.

Authors:  Eric Tan; Barbara Erwin; Shale Dames; Tanya Ferguson; Megan Buechel; Bruce Irvine; Karl Voelkerding; Angelika Niemz
Journal:  Biochemistry       Date:  2008-08-26       Impact factor: 3.162

4.  Molecular beacon probes-base multiplex NASBA Real-time for detection of HIV-1 and HCV.

Authors:  S Mohammadi-Yeganeh; M Paryan; S Mirab Samiee; V Kia; H Rezvan
Journal:  Iran J Microbiol       Date:  2012-06

5.  Multiple strategies to improve sensitivity, speed and robustness of isothermal nucleic acid amplification for rapid pathogen detection.

Authors:  Yanhong Tong; Bertrand Lemieux; Huimin Kong
Journal:  BMC Biotechnol       Date:  2011-05-11       Impact factor: 2.563

6.  Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum.

Authors:  Gunnar Schalasta; Andrea Speicher; Anna Börner; Martin Enders
Journal:  J Clin Microbiol       Date:  2016-02-10       Impact factor: 5.948

Review 7.  Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential.

Authors:  Stacy G Beal; Naziheh Assarzadegan; Kenneth H Rand
Journal:  Expert Rev Mol Diagn       Date:  2016-01-11       Impact factor: 5.225

Review 8.  [Safety of blood and blood products: test methods for the detection of hepatitis B, C, and E virus].

Authors:  Johanna Mitterreiter; Heinrich Scheiblauer; Sarah Fiedler; Julia Kreß
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-01-13       Impact factor: 1.513

9.  Life beyond PCR: alternative target amplification technologies for the diagnosis of infectious diseases, part I.

Authors:  Christine C Ginocchio
Journal:  Clin Microbiol Newsl       Date:  2004-08-11

Review 10.  Evolving gene targets and technology in influenza detection.

Authors:  Anthony P Malanoski; Baochuan Lin
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.